Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma
This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of ovarian epithelial carcinoma
Ovarian Epithelial Carcinoma
DRUG: SZ011 CAR-NK
Number of Adverse Events (AEs), To evaluate the safety of SZ011 CAR-NK Cells, Up to 6 months after infusion|Objective response rate (ORR), To evaluate the ORR of SZ011 CAR-NK Cells, Up to 6 months after infusion|Overall survival (OS), To determine the anti-tumor effectivity of SZ011 CAR-NK Cells, Up to 6 months after infusion|Progression-free survival (PFS), To determine the anti-tumor effectivity of SZ011 CAR-NK Cells, Up to 6 months after infusion
This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of ovarian epithelial carcinoma